Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06410963
Other study ID # Reactivate
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 1, 2024
Est. completion date December 31, 2025

Study information

Verified date May 2024
Source Örebro University, Sweden
Contact Tove Axelsson-Landberg, MSc
Phone +46 736318264
Email tove.axelssonlandberg@regionorebrolan.se
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Recurrent or persistent pain and psychological distress are alarmingly common problems among adolescents, in Sweden as well as globally. They often co-occur and have been shown to be predictors of sustained problems in adulthood. Adequate treatment early on in the development of problems has been shown important in order to decrease the risk of sustained problems in adulthood but available treatments have only modest effects. There is thus a need for treatment development, not in the least for (secondary) preventative purposes. The aim of this project is therefore to develop an evidence based and cost-effective secondary preventative intervention. Specifically, this project aims to develop and test a physiotherapist led treatment for adolescents with recurrent or persistent pain and psychological distress based upon graded exposure to physical activity and reactivation.


Description:

See description of arms and intervention.


Recruitment information / eligibility

Status Recruiting
Enrollment 35
Est. completion date December 31, 2025
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 12 Years to 19 Years
Eligibility Inclusion Criteria: - Age 12-19 - Psychological distress, such as anxiety, depressive symptoms or stress, =2 on a numeric rating scale 0-6 (0=not at all, 6=to a great extent) - Persistent (consistently or weekly recurrent) musculoskeletal pain problems for =3 months, with pain intensity =2 on a numeric rating scale 0-6 (0=not at all, 6=to a great extent) - Presence of avoidance behaviour and/or or worry about symptoms/problems, =1 on a numeric rating scale 0-6 (0=not at all, 6=to a great extent); > 50 on at least one activity of the PHODA. - Swedish speaking and able to fill out questionnaires Exclusion Criteria: - Serious/malignant disease - Participation in other rehabilitation program - Severe mental health problems - Substance abuse - Severe learning disabilities

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Reactivate
The study period is 84 days (12 weeks). Depending on the length of the baseline period (randomly assigned to be 7, 14 or 21 days), the treatment period varies between 63-77 days and contains 6-11 sessions. The intervention consists of 2-4 educational sessions in pain mechanisms and fear avoidance and 4-9 sessions of individually tailored intervention with graded exposure and reactivation to avoided physical activities. Intervention will take place from one time per week to one time every two weeks, 30-60 minutes per session. Number of treatment sessions will depend on when the individual participants' goals are considered reached. If necessary, given the participants consent, their legal guardians will be invited to attend the sessions.

Locations

Country Name City State
Sweden Region Örebro county Örebro

Sponsors (2)

Lead Sponsor Collaborator
Örebro University, Sweden Region Örebro County

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Other Treatment Inventory of Costs in Patients with psychiatric disorders (Tic-P), medical resources Change in use of medical resources. Dichotomous scale completed by open ended answers if answer is yes. baseline, 12 weeks, 6 months after terminated intervention
Other Treatment Inventory of Costs in Patients with psychiatric disorders (Tic-P), school absence Change in school abcense. Dichotomous scale completed by open ended answers if answer is yes. One question is completed by one question with Numerical Rating Scale 1-10 (higher values, worse outcome) if answer is yes. baseline, 12 weeks, 6 months after terminated intervention
Other Accelerometer Change in physical activity, digital device counting steps 7 days of the first week of baseline (randomly assigned to be 7, 14 or 21 days). 7 days assessment 6 months after terminated assessment.
Primary Activity engagement change Change in self-rated activity engagement. Numerical Rating Scale, range 0-6 (1 question: lower values, worse outcome, 1 question: Lower values, better outcome ) repeated daily through phase A (randomly assigned to be 7, 14 or 21 days) and treatment phase B (9-11 weeks). Total time frame of assessment is 12 weeks (84 days). 7 days assessment 6 months after terminated intervention
Primary Symptom distress change Change in self-rated distress about symptoms. Numerical Rating Scale, range 0-6 (3 questions, higher values, worse outcome) repeated daily through phase A (randomly assigned to be 7, 14 or 21 days) and treatment phase B (9-11 weeks). Total time frame of assessment is 12 weeks (84 days). 7 days assessment 6 months after terminated intervention.
Secondary Functional Disability Inventory (FDI) change Change in functional disability. Descriptive Rating Scale, range 0-64 (higher values, worse outcome) baseline, after treatment phase B (12 weeks), 6 months after terminated intervention
Secondary Center of Epidemiological Studies Depression Scales for Children (CES-DC) change Change in depressive symptoms. Descriptive Rating Scale, range 0-60 (higher values, worse outcome) baseline, after treatment phase B (12 weeks), 6 months after terminated intervention
Secondary The Pediatric Quality of Life Acute version (PedsQL) PedsQLâ„¢ Change in quality of life. Descriptive Rating Scale, range 0-92 (higher values, worse outcome) baseline, after treatment phase B (12 weeks), 6 months after terminated intervention
Secondary Change in psychological distress Change in self-related symptoms of psychological distress. Numerical Rating Scale, range 0-6 (3 questions, higher values, worse outcome) repeated daily through phase A (randomly assigned to be 7, 14 or 21 days) and treatment phase B (9-11 weeks). Total time frame of assessment is 12 weeks (84days). 7 days assessment 6 months after terminated assessment.
Secondary Pain change Change in self-related pain symptoms. Numerical Rating Scale range 0-6 (higher values, worse outcome) repeated daily through phase A (randomly assigned to be 7, 14 or 21 days) and treatment phase B (9-11 weeks). Total time frame of assessment is 12 weeks (84days). 7 days assessment 6 months after terminated assessment.
Secondary Fear of Pain Questionnaire Children Short-form (FOPQ-C SF) change Change in fear of pain. Descriptiv Rating Scale, range 0-40 (higher values worse outcome) baseline, after treatment phase B (12 weeks), 6 months after terminated intervention
Secondary The Photograph Series of Daily Activities for youth (PHODA) change - short Change in percieved harmfulness. Photographs with 50 activities, rated on a Subjective Self-rating Scale, range 0-100mm/item (higher values, worse outcome) First session after baseline (randomly assigned to be 7, 14 or 21 days), after treatment phase B (12 weeks)
See also
  Status Clinical Trial Phase
Completed NCT01659073 - Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation N/A
Recruiting NCT05914311 - Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration N/A
Recruiting NCT05422456 - The Turkish Version of Functional Disability Inventory
Enrolling by invitation NCT05422443 - The Turkish Version of Pain Coping Questionnaire
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04385030 - Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury N/A
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05103319 - Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
Completed NCT03687762 - Back on Track to Healthy Living Study N/A
Completed NCT04171336 - Animal-assisted Therapy for Children and Adolescents With Chronic Pain N/A
Completed NCT03179475 - Targin® for Chronic Pain Management in Patients With Spinal Cord Injury Phase 4
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Recruiting NCT06060028 - The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain N/A
Recruiting NCT06204627 - TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain N/A
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Completed NCT00983385 - Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics Phase 3
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Terminated NCT03538444 - Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder N/A
Not yet recruiting NCT05812703 - Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain